1. Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. Issue 6 (June 2021) Authors: Pérez-García, José Manuel; Gebhart, Geraldine; Ruiz Borrego, Manuel; Stradella, Agostina; Bermejo, Begoña; Schmid, Peter; Marmé, Frederik; Escrivá-de-Romani, Santiago; Calvo, Lourdes; Ribelles, Nuria; Martinez, Noelia; Albacar, Cinta; Prat, Aleix; Dalenc, Florence; Kerrou, Khaldoun; Colleoni, Mar... Journal: Lancet oncology Issue: Volume 22:Issue 6(2021) Page Start: 858 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle. Issue 1 (6th October 2018) Authors: Bartelink, Imke H.; Jones, Ella F.; Shahidi‐Latham, Sheerin K.; Lee, Pei Rong Evelyn; Zheng, Yanan; Vicini, Paolo; van 't Veer, Laura; Wolf, Denise; Iagaru, Andrei; Kroetz, Deanna L.; Prideaux, Brendan; Cilliers, Cornelius; Thurber, Greg M.; Wimana, Zena; Gebhart, Geraldine Journal: Clinical pharmacology & therapeutics Issue: Volume 106:Issue 1(2019) Page Start: 148 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗